Analysis Group Team Coauthors Study on Health Care Resource Utilization and Costs in US Patients with GERD, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia

July 6, 2023

An Analysis Group team has coauthored a study examining health care resource utilization and costs among patients with gastroesophageal reflux disease (GERD), Barrett’s esophagus (BE), and Barrett’s esophagus-related neoplasia (BERN). GERD is a risk factor for both BE and BERN, and BE and BERN are, in turn, risk factors for esophageal cancer. As esophageal adenocarcinoma is one of the most lethal cancers in the US, the study authors aimed to provide a comprehensive, current assessment of real-world economic outcomes related to the cancer’s precursors.

Managing Principal Annie Guérin and Vice President Dominick Latrémouille-Viau, in collaboration with researchers from Exact Sciences, the University of Kansas School of Medicine, the Kansas City VA Medical Center, and the Perelman School of Medicine at the University of Pennsylvania, drew from a large, de-identified US insurance claims database. The authors found that GERD, BE, and BERN all incurred significant health care resource utilization and associated costs, with substantially higher rates as disease progressed to esophageal cancer. In conclusion, the authors report that these findings provide insights of potential value to decisions on the allocation of resources and management of patients with GERD, BE, and BERN, underscoring the need for frequent monitoring for early identification of high-risk patients before they have reached an advanced disease state, with the goal of improving both clinical and economic outcomes in this population.

The study, “Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States,” appeared in the Journal of Health Economics Outcomes Research in April 2023.

Read the study